Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001819790-25-000057
Filing Date
2025-03-20
Accepted
2025-03-20 21:49:13
Documents
1
Period of Report
2025-03-18

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1742521746.html 4  
1 FORM 4 wk-form4_1742521746.xml 4 6389
  Complete submission text file 0001819790-25-000057.txt   7816
Mailing Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618
Business Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618 (949) 409-9820
Tarsus Pharmaceuticals, Inc. (Issuer) CIK: 0001819790 (see all company filings)

EIN.: 814717861 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 15440 LAGUNA CANYON ROAD, SUITE 160 IRVINE CA 92618
Business Address
Wahl Bryan (Reporting) CIK: 0001841401 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39614 | Film No.: 25758375